2019 American Transplant Congress
Reduction of Pre-Existing Alloantibodies in Highly Sensitized Belatacept-Treated Kidney Recipients
*Purpose: Recent evidence suggests that belatacept reduces the durability of pre-existing antibodies to class I and class II human leukocyte antigens (HLA). Belatacept has a…2019 American Transplant Congress
A Novel Apparatus Mimicking Hypertensive Kidney With Primary Cultured Human Kidney Cells Using Rotational Force: Application To In Vitro Drug Screening In Kidney Transplant Recipients
*Purpose: Cell culture is an essential part of the development for various medical technologies such as identifying the cause of the disease and developing new…2019 American Transplant Congress
Incidence, Risk Factors, Outcomes and Clinical Management of BK Viremia in the Modern Era of Kidney Transplantation
Toronto General Hospital, Toronto, ON, Canada
*Purpose: BK viremia is endemic among kidney transplant recipients (KTR). Previous work has not compared the incidence, risk factors, and outcomes of any vs. clinically…2019 American Transplant Congress
Immunologic Outcomes In Recipients Of Orthotopic Liver Transplant Induced Only With Steroids
The University of Texas Medical Branch, Galveston, TX
*Purpose: Liver allografts are resistant to antibody mediated rejection (AMR) in the presence of preformed alloantibodies. In most cases donor specific antibodies (DSAs) disappear a…2019 American Transplant Congress
Post-Transplant Cancer Following Living Donor HLA-Incompatible Kidney Transplantation
1Johns Hopkins University, Baltimore, MD, 2University of Alabama, Birmingham, AL
*Purpose: Incompatible living donor kidney transplantation (ILDKT) recipients require increased immunosuppression compared to their compatible living donor kidney transplant (CLDKT) counterparts. This continued exposure to…2019 American Transplant Congress
Early Use of Everolimus Plus Reduced Tacrolimus vs Standard Tacrolimus in De Novo Livertransplant Recipients: 12 Months Efficacy and Safety Data from HEPHAISTOS Study
1Study Group, Hephaistos, Germany, 2Novartis Pharma GmbH, Nuernberg, Germany
*Purpose: The HEPHAISTOS study was set up to compare early use of everolimus [EVR] combined with reduced tacrolimus [rTAC] versus standard-dose tacrolimus [TAC-C) in de…2019 American Transplant Congress
Kidney Xenotransplantation from Genetically Engineered Pigs to Baboons with FDA-Approved Immunosuppressive Therapy
*Purpose: Genetically-engineered pigs might present a solution to the critical shortage of organs for clinical transplantation. The aims of this study were to evaluate the…2019 American Transplant Congress
Improving Medication Adherence and Outcomes in Adult Kidney Transplant Patients Using SystemCHANGETM: Results of the Medication Adherence Given Individual Change (MAGIC) Randomized Clinical Trial
*Purpose: Medication non-adherence is an obdurate problem associated with poor outcomes and staggering costs. Even with multi-faceted interventions, effect sizes reported in meta-analyses of medication…2019 American Transplant Congress
Beta2-Adrenergic Receptor Activation Prolongs Survival of Vascularized Composite Tissue Allotransplants in a Murine Model
*Purpose: Transplantation of faces, hands, and limbs using vascularized composite allotransplantation (VCA) has faced significant challenges hindering its routine implementation in the clinic. One critical…2019 American Transplant Congress
Conversion from Tacrolimus Immediate Release to Tacrolimus Extended Release (Envarsus XR®): A Real World Cohort Highlighting Dosing Variability among Patients
*Purpose: Tacrolimus extended release (TacER) (Envarsus XR®) has become an attractive alternative to tacrolimus immediate release (TacIR) due to its once daily dosing scheme, favorable…
- « Previous Page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- …
- 138
- Next Page »